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Background: Limited pharmacological options exist for patients with resistant hypertension (RH). Sympathetic renal denervation therapy (RDN) is 
a novel approach which has been evaluated in multiple small studies. We sought to determine the current effectiveness and safety of RDN on RH.
methods: We performed a systematic review and meta-analysis of published studies evaluating the effect of RDN in patients with RH. Data was 
extracted in duplicate and analyzed by comparing the mean achieved difference in blood pressure (BP) with RDN using random-effects meta-
analytic models. Studies were stratified according to controlled vs. uncontrolled design.
results: We identified 2 randomized controlled trials (N=133), 1 observational study with a control group (N=50) and 9 uncontrolled observational 
studies (N=396) evaluating the effect of RDN on RH. These studies included 579 patients followed for a weighted average follow-up of 6.7 months 
(range 1 to 24 months). Five different RDN catheters were used among the 12 studies. In controlled studies, there was a reduction in mean systolic 
and diastolic BP at 6 months of -28.9 (95% CI -37.2, -20.6) and -11.0 (95% CI -16.4, -5.7) mmHg, respectively, compared to medically treated 
patients (for both, p<0.0001). In uncontrolled studies, there was a reduction in mean systolic and diastolic BP at 6 months of -25.0 (95% CI -29.9, 
-20.1) and -10.0 (95% CI -12.5, -7.5) mmHg, respectively, compared to pre-RDN values (for both, p<0.00001). There was no significant difference in 
the effect of RDN according to the catheter employed. Overall, the non-responder rate was 13.4% (range 0-45%). Reported procedural complications 
included 1 renal artery dissection and 4 pseudoaneurysms at the site of arterial puncture.
conclusions: RDN results in a substantial reduction in mean BP at 6 months in patients with RH. The magnitude of decrease in BP was similar 
irrespective of controlled vs. uncontrolled study design and catheter employed. Large randomized controlled trials with long-term follow-up are 
needed to confirm the sustained efficacy and safety of RDN.
